盐酸埃克替尼治疗终末期非小细胞肺癌多发脑转移放疗失败后的临床效果  

Analysis of icotinib hydrochloride in the treatment for recurrent or progressive brain metastases after radiation in patients with end-stage non-small cell lung cancer

作　　者：曾越灿[1] 吴荣[1] 迟峰[1] 邢锐[1] 蔡炜嵩[1] 肖玉平[2] 辛彦[2] 王乃乾[2] 

机构地区：[1]中国医科大学附属盛京医院肿瘤科,沈阳110022 [2]中国医科大学附属第一医院第四肿瘤研究所

出　　处：《中国综合临床》2014年第8期804-807,共4页Clinical Medicine of China

基　　金：国家自然科学基金资助项目（81201803）

摘　　要：目的探讨盐酸埃克替尼治疗终末期（ECOGPS评分3,4分）非小细胞肺癌多发脑转移放疗后失败患者的效果。方法终末期非小细胞肺癌多发脑转移放疗后失败患者33例，17例接受盐酸埃克替尼治疗，16例不接受盐酸埃克替尼治疗和其他放化疗。结果2个月时，治疗组17例中9例为部分缓解，4例稳定，4例疾病进展，无完全缓解病例。对照组16例中4例稳定，其余12例疾病进展，无完全缓解病例。治疗组中位生存期为95d，对照组中位生存期为60d（P=0．007）。结论盐酸埃克替尼可延长终末期非小细胞肺癌多发脑转移放疗后失败患者的生存期。Objective To investigate the efficacy of icotinib hydrochloride in the treatment for recurrent or progressive brain metastases after radiation in patients with end-stage （ECOG PS score 3 -4 points） non-small cell lung cancer. Methods Thirty-three patients with recurrent or progressive brain metastases after radiation were divided into treatment group （n = 17） and the control group （n = 16 ）. Patients in the treatment group were received icotinib hydrochloride treatment, in the control group did not receive icotinib hydrochloride treatment and any other chemoradiotherapy. Results There were 9 patients with partial remission,4 patients with stable disease,4 patients with disease progression,and rio patients with complete remission in the treatment group after 2 months of treatment. There were 4 patients with stable disease, 12 patients with disease progression, and no patients with complete remission in the control group. The median survival time was 95 d in the treatment group and 60 d in the control group（P = O. 007）. Conclusion Icotinib hydrochloride could improve the survival and disease control rate for recurrent or progressive brain metastases patients after radiation with end-stage non-small cell lung cancer.

关 键 词：盐酸埃克替尼 非小细胞肺癌 脑转移 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]